Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: May 28, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 1643 miles
M D Anderson Cancer Center

VISITS: Monthly visits, ongoing


NCT ID: NCT03218826

AZD8186 and Docetaxel for Advanced Breast Cancer with PTEN or PIK3C-beta Mutations

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel Scientific Title

To determine the best dose and effects (good and bad) of the targeted therapy AZD8186 when it is used with a chemotherapy to treat tumors that test positive for PTEN or PIK3C-beta mutations.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that will potentially respond to the chemotherapy drug docetaxel (Taxotere®).    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD8186, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV, monthly, ongoing</li> <li class="seamTextUnorderedListItem">2 biopsies</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD8186 is an experimental targeted therapy that works by inhibiting PI3K proteins and is designed for cancers that are characterized as being deficient in PTEN.</li> <li class="seamTextUnorderedListItem">Taxotere is a chemotherapy commonly used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancers.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PTEN or PIK3CB</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03218826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/risk/factors/genetics' target='_blank'>Breastcancer.org: Genetics</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3kbeta-inhibitor-azd8186' target='_blank'>NCI Dictionary: AZD8186</a> </li></ul>
See more